It has been demonstrated that the combined use of tubulin inhibitors and ICIs was successful for the treatment of non-small cell lung cancer [86–88], because tubulin inhibitors enhanced CD4 + and CD8+ T cell activity [89], inhibited Tregs [90], induced dendritic cell maturation, and increased M1 macrophages [91, 92]. This evidence concerns the gene CD4 and non-small cell lung carcinoma.